Uncategorized

Merck, Gilead serve ‘sweet and sour’ spread after HIV win, cancer stumble

Merck, Gilead serve ‘sweet and sour’ spread after HIV win, cancer stumble

Published

3 days ago

on

While Merck and Gilead Sciences reported back-to-back late-stage victories for their weekly HIV pill, the partners also discontinued a Phase 3 program for their cancer combo after disappointing lung cancer survival data.​ ​Read More

Related Topics:

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version